APP下载

Esophageal granular cell tumor: A case report

2022-12-19YaLanChenJingZhouHuiLingYu

World Journal of Clinical Cases 2022年19期

Ya-Lan Chen,Jing Zhou,Hui-Ling Yu

Abstract

Key Words: Esophageal granular cell tumor; Esophagoscopy; Endoscopic mucosal resection; Immunohistochemical; Case report

lNTRODUCTlON

Granular cell tumor (GCT) is a rare disease that was first detected in the tongue by Abrikossoff in 1926[1]. Usually, GCT develops on the skin or oral mucosa, especially in the tongue[2]. In 1931, Abrikossoff first described GCT in the esophagus, which is currently the most common site of involvement within the gastrointestinal tract, primarily the distal segment of the esophagus[3]. Most esophageal granular cell tumor (eGCT) are benign, with fewer than 2% of clinical cases being malignant[4].

In this report, we describe an eGCT that had developed in the middle of the esophagus, and we conducted a systematic review of 72 cases reported in China. The clinical data were analyzed to conclude the characteristics of eGCT so as to raise clinical awareness.

CASE PRESENTATlON

Chief complaints

A 2-year history of acid reflux heartburn and a choking sensation during eating for the past month.

History of present illness

A 52-year-old female patient with a 2-year history of acid reflux heartburn and a choking sensation during eating for the past month was admitted to our hospital. Symptoms could be alleviated by oral administration of acid suppressants. We performed gastroscopy to establish the cause of the disease (June 2020). Upon admission, vital signs were within normal limits. Cardiopulmonary and abdominal examination did not show any abnormalities. Physical examination did not reveal a significant weight loss. There was no clinically significant family history, the patient had no smoking or drinking habits, and neither did she have a history of using special drugs or exposures to toxic substances.

Under white light gastroscopy, there was a humulous-shaped eminence about 26 cm away from the incisor. Mucosa was smooth and clearly demarcated, with a size of about 0.4 cm and a hard yellow texture (Figure 1). Biopsy of the mass was performed. Pathological HE staining showed that tumor cells were closely arranged in a nest or strip shape, cell sizes were the same, the cytoplasm was rich, there was a large number of eosinophilic granulosa cells, while the nucleus was small, round and centered (Figure 2). The diagnosis of GCT was established by immunohistochemical staining, which was positive for the glycoprotein S100 protein, CK (+), SMA (-) (Figure 3).

History of past illness

The patient had an unremarkable medical history.

Personal and family history

There was no clinically significant family history, the patient had no smoking or drinking habits, and neither did she have a history of using special drugs or exposures to toxic substances.

Physical examination

Cardiopulmonary and abdominal examination did not show any abnormalities.

Laboratory examinations

No abnormality was found in blood routine examination and liver and kidney function. CEA, CA125 and CA199 were normal.

Figure 1 Endoscopy of esophageal granular cell tumor.

Figure 2 HE staining X200. The tumor cells were closely arranged in a cordlike pattern,

Figure 3 lmmunohistochemical S100 positive. A: Contrast diagram not stained with S100; B and C: the nucleus and cytoplasm of granulosa cell tumor are brown and yellow by S-100 staining.

Imaging examinations

Under white light gastroscopy, there was a humulous-shaped eminence about 26 cm away from the incisor. Mucosa was smooth and clearly demarcated, with a size of about 0.4 cm and a hard yellow texture.

FlNAL DlAGNOSlS

Esophageal granular cell tumor.

TREATMENT

Because the volume of the mass was less than 1 cm, re-examination was performed by gastroscopy.

OUTCOME AND FOLLOW-UP

Her patient was diagnosed with granulosa cell tumor, but endoscopic surgery was not performed due to the small size of the tumor, and the tumor size did not increase during the 1-year follow-up.

DlSCUSSlON

The esophageal granular cell tumor is extremely uncommon. It was first described by Abrikossoff in 1931, when he reported on a patient with such tumors found in the esophagus. However, eGCT is an unusual developmental site for GCTs. Johnston and Helwig[3] reported on 75 GCTs of the gastrointestinal tract, most of them being located in the esophagus, which accounts for about 1 to 2 % of GCTs. Majority of these GCTs are often located in the esophageal distal part, followed by the colon, perianal region, stomach, small intestines and appendix[5].

Recently, we conducted a literature search in PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) were searched for all studies published till July 2021. Using relevant keywords “esophageal granular cell tumor” in Chinese, and found 71 cases. The patient described in this report is the 72ndcase, which confirms that Esophageal GCTs are rare. Of the 72 patients, 44 were male while 28 were female, their ages ranged from 28 years to 66 years, with a mean of 46 years. Regarding clinical manifestations, 30 patients exhibited upper abdominal pain and fullness while 10 patients had swallowing discomforts, acid reflux and heartburn. Regarding esophageal location, they were in the upper (n= 9), middle (n= 18), and distal (n= 45) parts. Most of the tumors appeared yellow. Maximum diameters of tumors ranged from 0.4 cm to 5.5 cm, however, most of them were within 1 cm. A total of 35 patients had been subjected to endoscopic ultrasonography: 22 cases originated from the submucosa, 6 cases from the mucosal layer, 5 cases from the mucosal muscularis, and 2 cases from muscularis propria. One case of malignant granulosa cell tumor was pathologically confirmed (1.38%).

Usually, eGCT, which is diagnosed by gastroscopy, clinically manifests as a slow-growing round tumor with somewhat undefined margins measuring between 5-20 mm in diameter[6]. It appears yellow or white, with a hard, fixed texture. Endoscopy can be performed to provide additional information on the layer of origin and tumor extension[7]. Most eGCTs originate from the submucosa, it doesn't invade serosal layers of the esophagus. Histologic evaluation is the gold standard method for diagnosis.

Clinically, eGCT is a rare soft lesion with potential malignant tissue neoplasms. Its tissue origin is unclear. Various cell lines, derived from Schwann cells of the neuroectoderm have been proposed to be possible causes of GCT[8]. GCT exhibits typical pathomorphology and immunohistochemical characteristics. The main characteristics consist of nests of round or polygonal large cells with round, central nuclei and with eosinophilic cytoplasms as well as markedly enlarged lysosomes with a granular appearance[3]. Immunohistochemistry expressing S-100, CD68 and Vimentin, did not express CD117, CD34, SMA, Desmin, CK. Observation of these tumors is indicated unless the patient is symptomatic or the tumor is greater than 1 cm or has atypical endoscopic ultrasonographic or histologic features[7]. The most preferred treatment option for eGCT is endoscopic resection, which is highly associated with bleeding and perforation[9,10]. Although most granulocytomas are benign and grow slowly, about 2% of granulocytomas are malignant, which require surgery. For clinical evaluation, tumor diameter ≥ 3 cm is considered malignant, however, malignancy is also suspected if the tumor grows rapidly and forms ulcers[11]. The rapid growth of malignant tumors can lead to metastasis, especially to regional lymph nodes, lungs, liver, and bone[12].

CONCLUSlON

In conclusion, the gastro- intestinal tract is an unusual developmental site for a GCTs, with the esophagus being the most common site of origin. Its diagnosis depends on characteristic pathomorphologies and detection of the S-100 protein. Endoscopic mucosal resection is the preferred therapeutic method.

ACKNOWLEDGEMENTS

We sincerely thank the patient and their family for their support and dedication.

FOOTNOTES

Author contributions:Chen YL wrote the initial draft and drafted the data and figures; Yu HL revised the draft; Zhou J provided clinical supervision and edited the manuscript; All authors approved the final version of the manuscript.

lnformed consent statement:The study participant provided informed written consent prior to the study.

Conflict-of-interest statement:The authors declare that there are no conflicts of interest.

CARE Checklist (2016) statement:The article is consistent for CARE Checklist (2016) statemen.

Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin:China

ORClD number:Ya-Lan Chen 0000-0002-0680-8006; Jing Zhou 0000-0002-8876-195X; Hui-Ling Yu 0000-0002-5476-5661.

S-Editor:Ma YJ

L-Editor:Filipodia

P-Editor:Ma YJ